Drug lookup | Fillwise

Listed in the December 27, 2023 extract; not in the current extract (Aug 26, 2026): Multipax (01927876), Novo-Hydroxyzin (00738832), Multipax (01938835), Multipax (01927884). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-08-26.xml.

HYDROXYZINE HCL

All products: not a benefit

Other products in the same Health Canada class (N05B) — coverage varies; not interchangeable

Alprazolam (Xanax): general benefit, Not a benefit
Bromazepam (Lectopam): general benefit, Not a benefit
Chlordiazepoxide (Librium): general benefit, Not a benefit
Clorazepate dipotassium (Tranxene): general benefit, Not a benefit
Diazepam (Diazepam Injection USP): general benefit, Limited Use 481, Not a benefit
Lorazepam (Apo-Lorazepam): general benefit, Not a benefit

1 more in the class list below

Hydroxyzine · DIN 00646059 · 10mg · capsule

Listed, not a benefitMarketed · checked 2026-09-02

StatusListed, not a benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Hydroxyzine · DIN 00646059 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2019-02-14 · brand HYDROXYZINE · ATC N05BB01 HYDROXYZINE · form Capsule · route Oral · ingredients HYDROXYZINE HYDROCHLORIDE 10 MG · company Aa pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Hydroxyzine: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=7393 · Verify on the e-Formulary ↗ (DIN 00646059)

Source record

DIN 00646059: Hydroxyzine Raw flags: notABenefit=Y, sec3=Y Item: 281608041; group id 494; item number 1266; lccId None; manufacturer id AAP Source form: Cap; strength: 10mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00646059 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=7393

Interchangeable products

Atarax · DIN 00024376 · not recorded Novo-Hydroxyzin · DIN 00738824 · not recorded

Shortage status: resolved shortage (ended 2025-10-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00646059

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Hydroxyzine · DIN 00646024 · 25mg · capsule

Listed, not a benefitMarketed · checked 2026-09-02

StatusListed, not a benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Hydroxyzine · DIN 00646024 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2019-03-28 · brand HYDROXYZINE · ATC N05BB01 HYDROXYZINE · form Capsule · route Oral · ingredients HYDROXYZINE HYDROCHLORIDE 25 MG · company Aa pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Hydroxyzine: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Source record

DIN 00646024: Hydroxyzine Raw flags: notABenefit=Y, sec3=Y Item: 281608040; group id 494; item number 1267; lccId None; manufacturer id AAP Source form: Cap; strength: 25mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00646024 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=7392

Interchangeable products

Atarax · DIN 00024384 · not recorded

Shortage status: resolved shortage (ended 2025-07-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00646024

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Hydroxyzine · DIN 00646016 · 50mg · capsule

Listed, not a benefitMarketed · checked 2026-09-02

StatusListed, not a benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Hydroxyzine · DIN 00646016 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2019-01-24 · brand HYDROXYZINE · ATC N05BB01 HYDROXYZINE · form Capsule · route Oral · ingredients HYDROXYZINE HYDROCHLORIDE 50 MG · company Aa pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Hydroxyzine: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Source record

DIN 00646016: Hydroxyzine Raw flags: notABenefit=Y, sec3=Y Item: 281608039; group id 494; item number 1268; lccId None; manufacturer id AAP Source form: Cap; strength: 50mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00646016 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=7391

Interchangeable products

Atarax · DIN 00024392 · not recorded Novo-Hydroxyzin · DIN 00738840 · not recorded

Shortage status: resolved shortage (ended 2025-09-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00646016

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Novo-Hydroxyzin · DIN 00738824 · 10mg · capsule

Listed, not a benefitDormant since 2022-01-25 · checked 2026-09-02 · What does dormant mean?

StatusListed, not a benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Novo-Hydroxyzin · DIN 00738824 Manufacturer: Novopharm Ltd.; listing date 1996-10-01 Health Canada: Dormant since 2022-01-25 · brand NOVO-HYDROXYZIN · ATC N05BB01 HYDROXYZINE · form Capsule · route Oral · ingredients HYDROXYZINE HYDROCHLORIDE 10 MG · company Teva canada limited · schedule Prescription

Check this DIN again · Health Canada product record

Novo-Hydroxyzin: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=7442 · Verify on the e-Formulary ↗ (DIN 00738824)

Source record

DIN 00738824: Novo-Hydroxyzin Raw flags: notABenefit=Y, sec3=Y Item: 281608041; group id 494; item number 1266; lccId None; manufacturer id NOP Source form: Cap; strength: 10mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00738824 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=7442

Interchangeable products

Atarax · DIN 00024376 · not recorded Hydroxyzine · DIN 00646059 · not recorded

Shortage status: active shortage (reported 2014-03-26, last updated 2017-10-05) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00738824

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Dormant since 2022-01-25 — choose a marketed DIN from the same-category list.

Novo-Hydroxyzin · DIN 00738840 · 50mg · capsule

Listed, not a benefitDormant since 2022-01-25 · checked 2026-09-02

StatusListed, not a benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Novo-Hydroxyzin · DIN 00738840 Manufacturer: Novopharm Ltd.; listing date 1996-10-01 Health Canada: Dormant since 2022-01-25 · brand NOVO-HYDROXYZIN · ATC N05BB01 HYDROXYZINE · form Capsule · route Oral · ingredients HYDROXYZINE HYDROCHLORIDE 50 MG · company Teva canada limited · schedule Prescription

Check this DIN again · Health Canada product record

Novo-Hydroxyzin: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=7444 · Verify on the e-Formulary ↗ (DIN 00738840)

Source record

DIN 00738840: Novo-Hydroxyzin Raw flags: notABenefit=Y, sec3=Y Item: 281608039; group id 494; item number 1268; lccId None; manufacturer id NOP Source form: Cap; strength: 50mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00738840 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=7444

Interchangeable products

Atarax · DIN 00024392 · not recorded Hydroxyzine · DIN 00646016 · not recorded

Shortage status: resolved shortage (ended 2025-04-07); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00738840

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Dormant since 2022-01-25 — choose a marketed DIN from the same-category list.

Atarax · DIN 00024376 · 10mg · capsule

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2005-09-15 — choose a marketed DIN from the same-category list.Discontinued 2005-09-15 · checked 2026-09-02

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2005-09-15 — choose a marketed DIN from the same-category list.

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2005-09-15 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Atarax · DIN 00024376 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2005-09-15 · brand ATARAX CAP 10MG · ATC N05BB01 HYDROXYZINE · form Capsule · route Oral · ingredients HYDROXYZINE HYDROCHLORIDE 10 MG · company Erfa canada 2012 inc · schedule Prescription

Check this DIN again · Health Canada product record

Atarax: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=319 · Verify on the e-Formulary ↗ (DIN 00024376)

Source record

DIN 00024376: Atarax Raw flags: notABenefit=Y, sec3=Y Item: 281608041; group id 494; item number 1266; lccId None; manufacturer id PFI Source form: Cap; strength: 10mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00024376 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=319

Interchangeable products

Hydroxyzine · DIN 00646059 · not recorded Novo-Hydroxyzin · DIN 00738824 · not recorded

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00024376

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2005-09-15 — choose a marketed DIN from the same-category list.

Atarax · DIN 00024384 · 25mg · capsule

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2005-09-15 — choose a marketed DIN from the same-category list.Discontinued 2005-09-15 · checked 2026-09-02

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2005-09-15 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Atarax · DIN 00024384 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2005-09-15 · brand ATARAX CAP 25MG · ATC N05BB01 HYDROXYZINE · form Capsule · route Oral · ingredients HYDROXYZINE HYDROCHLORIDE 25 MG · company Erfa canada 2012 inc · schedule Prescription

Check this DIN again · Health Canada product record

Atarax: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=318 · Verify on the e-Formulary ↗ (DIN 00024384)

Source record

DIN 00024384: Atarax Raw flags: notABenefit=Y, sec3=Y Item: 281608040; group id 494; item number 1267; lccId None; manufacturer id PFI Source form: Cap; strength: 25mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00024384 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=318

Interchangeable products

Hydroxyzine · DIN 00646024 · not recorded

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2005-09-15 — choose a marketed DIN from the same-category list.

Atarax · DIN 00024392 · 50mg · capsule

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2005-09-15 — choose a marketed DIN from the same-category list.Discontinued 2005-09-15 · checked 2026-09-02

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2005-09-15 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Atarax · DIN 00024392 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2005-09-15 · brand ATARAX CAP 50MG · ATC N05BB01 HYDROXYZINE · form Capsule · route Oral · ingredients HYDROXYZINE HYDROCHLORIDE 50 MG · company Erfa canada 2012 inc · schedule Prescription

Check this DIN again · Health Canada product record

Atarax: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=317 · Verify on the e-Formulary ↗ (DIN 00024392)

Source record

DIN 00024392: Atarax Raw flags: notABenefit=Y, sec3=Y Item: 281608039; group id 494; item number 1268; lccId None; manufacturer id PFI Source form: Cap; strength: 50mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00024392 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=317

Interchangeable products

Hydroxyzine · DIN 00646016 · not recorded Novo-Hydroxyzin · DIN 00738840 · not recorded

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2005-09-15 — choose a marketed DIN from the same-category list.

Other drugs in the same formulary class (28:16:08 Tranquilizers) and how they are covered

Matched class: 28:16:08 Tranquilizers

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ARIPIPRAZOLE, ASENAPINE, BREXPIPRAZOLE, CARIPRAZINE, FLUPENTIXOL DECANOATE, FLUPENTIXOL DIHYDROCHLORIDE, PALIPERIDONE, PALIPERIDONE PALMITATE, PERICYAZINE, PIMOZIDE, ZIPRASIDONE HCL MONOHYDRATE, ZUCLOPENTHIXOL DECANOATE, ZUCLOPENTHIXOL DIHYDROCHLORIDE Some products covered without a code (check the product listing): ALPRAZOLAM, BROMAZEPAM, CHLORDIAZEPOXIDE, CHLORPROMAZINE, CLORAZEPATE DIPOTASSIUM, DIAZEPAM, FLUPHENAZINE HCL, HALOPERIDOL, HALOPERIDOL DECANOATE, LORAZEPAM, LOXAPINE SUCCINATE, LURASIDONE HYDROCHLORIDE, OLANZAPINE, OXAZEPAM, PERPHENAZINE, PROCHLORPERAZINE, QUETIAPINE, RISPERIDONE, TRIFLUOPERAZINE 28:16:08 Tranquilizers

ALPRAZOLAM

· 12 products · General benefit (6), Off-Formulary Interchangeable, not an ODB benefit (6) · strengths: 0.25mg, 0.5mg, 1mg, 2mg · Tab

BROMAZEPAM

· 8 products · Listed, not a benefit (3), General benefit (5) · strengths: 1.5mg, 3mg, 6mg · Tab

CHLORDIAZEPOXIDE

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 25mg · Cap

CLORAZEPATE DIPOTASSIUM

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 3.75mg, 7.5mg, 15mg · Cap

DIAZEPAM

· 10 products · Limited Use, codes 481 (1), General benefit (6), Listed, not a benefit (3) · strengths: 5mg/mL, 10mg/2mL, 15mg/3mL, 2mg, 5mg, 10mg · Inj Sol (Preservative Free), Rect Gel-2x 5mg Pk, Rect Gel-2x10mg Pk, Rect Gel-2x15mg Pk, Tab

LORAZEPAM

· 12 products · General benefit (9), Listed, not a benefit (3) · strengths: 0.5mg, 1mg, 2mg · Tab

OXAZEPAM

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 10mg, 15mg, 30mg · Tab

ARIPIPRAZOLE

· 70 products · General benefit · strengths: 720mg/2.4mL, 960mg/3.2mL, 300mg/Vial, 400mg/Vial, 2mg, 5mg, 10mg, 15mg, 20mg, 30mg · Inj Sol-Pref Syr, Prolong-Rel Inj Pd-Vial Pk, Tab

ASENAPINE

· 2 products · General benefit · strengths: 5mg, 10mg · SL Tab

BREXPIPRAZOLE

· 6 products · General benefit · strengths: 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg · Tab

CARIPRAZINE

· 4 products · General benefit · strengths: 1.5mg, 3mg, 4.5mg, 6mg · Cap

CHLORPROMAZINE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 25mg, 50mg, 100mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:08 and 21 more

Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.

What the Health Canada label says it is for

1 INDICATIONS HYDROXYZINE (hydroxyzine hydrochloride) is indicated in adults for: • Management of anxiety. • Pre-medication, such as preparation for dental procedures. • Management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses. • Control of nausea and vomiting, excluding nausea and vomiting of pregnancy (see 2 CONTRAINDICATIONS). 1.1 Pediatrics HYDROXYZINE is indicated in children for: • Pre-medication, such as preparation for dental procedures. • Management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses. • Control of nausea and vomiting, excluding nausea and vomiting of pregnancy (see 2 CONTRAINDICATIONS). 1.2 Geriatrics Evidence from clinical experience suggests that use in the geriatric population is associated with differences in safety or efficacy. https://pdf.hres.ca/dpd_pm/00074439.PDF PM date: August 29, 1985 Source product: HYDROXYZINE; DIN 00646016; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Novo-Hydroxyzin · DIN 00738824 Shortage status: active shortage (reported 2014-03-26, last updated 2017-10-05) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00738824

Check this DIN again

Health Canada: dormant products

Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)

Other review policies

For Hydroxyzine, Novo-Hydroxyzin, Atarax: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote

Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote

Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026